Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    FDA-&-EMA-New-Drug Approvals(Mid-2020 Recap)-insert
    X

    Find Hematology Drugs in Phase III Clinical Development in UNITED KINGDOM

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              GlaxoSmithKline

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              FDA Grants Priority Review of Nucala for Patients with Hypereosinophilic Syndrome

              Contact the Supplier

              Lead Product(s): Mepolizumab

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 27, 2020

              Details:

              If approval is obtained, it would make Nucala the first targeted biologic treatment for patients with this rare and life-threatening disease caused by eosinophilic inflammation.

              Akari Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              UNITED KINGDOM United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              Akari Therapeutics (AKTX) Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria Study

              Contact the Supplier

              Lead Product(s): Nomacopan

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 10, 2020

              Details:

              All patients treated with nomacopan achieved the primary endpoint of transfusion independence.

              Shield Therapeutics

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              United Kingdom United Kingdom

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chinaplas 2020

              Participation Not Confirmed

              Update your events

              China licence agreement for Feraccru/Accrufer

              Contact the Supplier

              Lead Product(s): Ferric Maltol

              Therapeutic Area: Hematology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Beijing Aosaikang Pharmaceutical

              Deal Size: $62.8 million Upfront Cash: $11.4 million

              Deal Type: Licensing Agreement January 08, 2020

              Details:

              Shield Therapeutics enters into an exclusive licence agreement for its lead product Feraccru®/Accrufer® with Beijing Aosaikang Pharmaceutical Co. Ltd. .

              PharmaCompass__DigitalAd